₹1,17,805 Cr
28.10
₹4,193 Cr
As on 14-Aug-2024 IST
₹-4.95
•
-0.42%
₹1,175.45
₹1,187.80
₹1,189.40
₹1,157.20
32,29,996
₹567.75 - 1,324.30
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| 69.83 | -0.40 | 17.93 | 79.81 | 27.98 | 39.74 | 18.19 |
|
BSE Sensex
| 9.50 | -1.76 | 8.70 | 21.10 | 12.58 | 16.44 | 11.80 |
|
BSE Healthcare
| 29.27 | 6.22 | 16.21 | 45.91 | 16.37 | 26.53 | 12.66 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| 64.11 | -13.08 | 0.99 | 87.51 | -27.35 | -19.44 | 21.55 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Zydus Lifesciences Ltd stood at ₹ 29,281 Cr as on 30-Jun-24
The share price of Zydus Lifesciences Ltd is ₹1,170.50 (NSE) and ₹1,170.75 (BSE) as of 14-Aug-2024 IST. Zydus Lifesciences Ltd has given a return of 27.98% in the last 3 years.
Zydus Lifesciences Ltd has a market capitalisation of ₹ 1,17,805 Cr as on 14-Aug-2024. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Zydus Lifesciences Ltd is 5.53 times as on 14-Aug-2024, a 9% discount to its peers’ median range of 6.09 times.
The P/E ratio of Zydus Lifesciences Ltd is 28.10 times as on 14-Aug-2024, a 34% discount to its peers’ median range of 42.30 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zydus Lifesciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Zydus Lifesciences Ltd.
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
The promoter of Zydus Lifesciences Ltd is Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees). Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees) owns 74.96 per cent of the total equity. The chairman of the company is Pankaj R Patel , and the managing director is Sharvil P Patel..
There is no promoter pledging in Zydus Lifesciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,16,345
|
|
|
1,27,170
|
|
|
1,17,030
|
|
|
1,12,890
|
| Zydus Lifesciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
21.62
|
|
Operating margin(%)
|
24.52
|
|
Net Margin(%)
|
19.88
|
|
Dividend yield(%)
|
0.26
|
Yes, TTM profit after tax of Zydus Lifesciences Ltd was ₹4,193 Cr.
₹1,17,804.84 Cr
₹20,615.30 Cr
₹4,192.50 Cr
₹1,357.60 Cr
₹768.60 Cr
74.98%
High
₹567.75 - 1,324.30
₹1.00
1,00,62,33,990
BSE: 532321, NSE: ZYDUSLIFE
Ahmedabad, Gujarat
www.zyduscadila.com
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products... segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust. Read more
Stocks 
Zydus Lifesciences Ltd.
Widely used:
